-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UF2RaymLfvRB9M4ncQQnC0iKXQePrvS86f5CLTLYjIil7aijO5wXiArmYqM3BmjB dknSjprBG4oM6DI7gjBsBg== 0000950133-99-001936.txt : 19990519 0000950133-99-001936.hdr.sgml : 19990519 ACCESSION NUMBER: 0000950133-99-001936 CONFORMED SUBMISSION TYPE: 13F-HR/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19980930 FILED AS OF DATE: 19990518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR/A SEC ACT: SEC FILE NUMBER: 028-06964 FILM NUMBER: 99629273 BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 13F-HR/A 1 FORM 13F 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: September 30, 1998 Check here if Amendment [ X ]; Amendment Number: 1 This Amendment (Check only one.): [ X ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Grafenauweg 4 Zug, Switzerland CH-6301 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Daniel Bugmann Title: SIGNING AUTHORITY Phone: (41-41) 724-5959 Signature, Place, and Date of Signing: /s/ DANIEL BUGMANN Zug, Switzerland 18 May 1999 - -------------------- ---- 2 Report Type (Check only one.): [ ] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [XX] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: Name Biotech Focus S.A. Biotech Invest S.A. -2- 3 Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 2 Form 13F Information Table Entry Total: 13 Form 13F Information Table Value Total:$580,698 (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Name 1 Biotech Focus S.A. 2 Biotech Invest S.A. 4 BB BIOTECH AG 30-SEP-98 FORM 13F INFORMATION TABLE
- ---------------------------------------------------------------------------------------------- COLUMN 5: ------------------------------ COLUMN 4: COLUMN 1: COLUMN 2: COLUMN 3: VALUE NAME OF ISSUER TITLE OF CLASS CUSIP (X$1,000) SHRS OR SH/ PUT/ PRN AMT PRN CALL - ---------------------------------------------------------------------------------------------- Alexion Pharmaceuticals Inc. Common Stock 01535110 $ 16,873 1,824,113 SH - ---------------------------------------------------------------------------------------------- Ariad Pharmaceuticals Inc. Common Stock 04033A10 $ 6,251 2,273,000 SH - ---------------------------------------------------------------------------------------------- Aurora Biosciences, Inc. Common Stock 05192010 $ 8,529 1,421,500 SH - ---------------------------------------------------------------------------------------------- Aviron Common Stock 05376210 $ 40,992 2,655,286 SH - ---------------------------------------------------------------------------------------------- Biochem Pharma, Inc. Common Stock 09058T10 $ 126,558 6,887,500 SH - ---------------------------------------------------------------------------------------------- Clinichem Development, Inc. Common Stock 18690610 $ 807 172,178 SH - ---------------------------------------------------------------------------------------------- CV Therapeutics, Inc. Common Stock 12666710 $ 11,325 1,969,647 SH - ---------------------------------------------------------------------------------------------- La Jolla Pharmaceutical Company Common Stock 50345910 $ 8,685 3,021,000 SH - ---------------------------------------------------------------------------------------------- - ------------------------------------------------------------------------------------------- COLUMN 8: COLUMN 6: COLUMN 7: VOTING AUTHORITY INVESTMENT OTHER MANAGERS ---------------------------------------- COLUMN 1: DISCTRETION NAME OF ISSUER SOLE SHARED NONE - ------------------------------------------------------------------------------------------- Alexion Pharmaceuticals Inc. DEFINED 1,824,113 NONE NONE - ------------------------------------------------------------------------------------------- Ariad Pharmaceuticals Inc. DEFINED 2,273,000 NONE NONE - ------------------------------------------------------------------------------------------- Aurora Biosciences, Inc. DEFINED 1,421,500 NONE NONE - ------------------------------------------------------------------------------------------- Aviron DEFINED 2 2,655,286 NONE NONE - ------------------------------------------------------------------------------------------- Biochem Pharma, Inc. DEFINED 1 6,887,500 NONE NONE - ------------------------------------------------------------------------------------------- Clinichem Development, Inc. DEFINED 172,178 NONE NONE - ------------------------------------------------------------------------------------------- CV Therapeutics, Inc. DEFINED 1,969,647 NONE NONE - ------------------------------------------------------------------------------------------- La Jolla Pharmaceutical Company DEFINED 3,021,000 NONE NONE - -------------------------------------------------------------------------------------------
5 - ----------------------------------------------------------------------------------------------- MedImmune, Inc. Common Stock 58469910 $ 252,072 3,893,000 SH - ----------------------------------------------------------------------------------------------- Sugen, Inc. Common Stock 86504110 $ 6,942 534,000 SH - ----------------------------------------------------------------------------------------------- Synsorb Biotech, Inc. Common Stock 87160V10 $ 5,438 2,115,810 SH - ----------------------------------------------------------------------------------------------- Transkaryotic Therapies, Inc. Common Stock 89373510 $ 67,476 2,811,500 SH - ----------------------------------------------------------------------------------------------- Vertex Pharmaceuticals, Inc. Common Stock 92532F10 $ 28,750 1,250,000 SH - ----------------------------------------------------------------------------------------------- COLUMN TOTALS $580,698 - -----------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------- MedImmune, Inc. DEFINED 1 3,893,000 NONE NONE - ----------------------------------------------------------------------------------------- Sugen, Inc. DEFINED 534,000 NONE NONE - ----------------------------------------------------------------------------------------- Synsorb Biotech, Inc. DEFINED 2,115,810 NONE NONE - ----------------------------------------------------------------------------------------- Transkaryotic Therapies, Inc. DEFINED 2 2,811,500 NONE NONE - ----------------------------------------------------------------------------------------- Vertex Pharmaceuticals, Inc. DEFINED 2 1,250,000 NONE NONE - ----------------------------------------------------------------------------------------- COLUMN TOTALS - -----------------------------------------------------------------------------------------
-----END PRIVACY-ENHANCED MESSAGE-----